drugset / Trial / NCT04394182

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19

NCT04394182

NaSingle-groupOpen-labelSupportive care

Summary

The host response against the coronavirus 2 (SARS-CoV-2) appears to be mediated by a 'cytoquine storm' developing a systemic inflammatory mechanism and an acute respiratory distress syndrome (ARDS), in the form of a bilateral pneumonitis, requiring invasive mechanical ventilation (IMV) in an important group of patients. In terms of preventing progression to the critical phase with the consequent need of admission to the intensive care units (ICU), it has been recently proposed that this inflammatory cytoquine-mediated process can be safely treated by a single course of ultra-low radiotherapy (RT) dose \< 1 Gy. The main purpose of the study was to analyze the efficacy of ultra low-dose pulmonary RT, as an anti-inflammatory intention in patients with SARS-Cov-2 pneumonia with a poor or no response to standard medical treatment and without IMV.

Timeline

Start
2020-04-21
Primary completion
2020-12-31
Completion
2022-03-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Azithromycin Small molecule 500 mg
Background Corticosteroid injection Unknown 250 mg
Background Heparin Other / unclassified
Background Hydroxychloroquine Small molecule 200 mg
Background Lopinavir Other / unclassified 100 mg
Background Piperacillin Small molecule 4 g Intravenous
Background Ritonavir Other / unclassified 400 mg
Background Tazobactam Small molecule 0.5 g Intravenous
Background Tocilizumab Monoclonal antibody 600 mg